+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myocardial Infarction - Pipeline Review, H1 2020

  • ID: 5017426
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 362 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • AstraZeneca Plc
  • Cadila Healthcare Ltd
  • CFM Pharma Holding BV
  • Generium
  • Innolife Co Ltd
  • MORE
Myocardial Infarction - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2020, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 17, 11, 51, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 2, 19 and 4 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • AstraZeneca Plc
  • Cadila Healthcare Ltd
  • CFM Pharma Holding BV
  • Generium
  • Innolife Co Ltd
  • MORE
  • Introduction
  • Myocardial Infarction - Overview
  • Myocardial Infarction - Therapeutics Development
  • Myocardial Infarction - Therapeutics Assessment
  • Myocardial Infarction - Companies Involved in Therapeutics Development
  • Myocardial Infarction - Drug Profiles
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Myocardial Infarction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Angion Biomedica Corp, H1 2020
  • Myocardial Infarction - Pipeline by Ankasa Regenerative Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Aposcience AG, H1 2020
  • Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Aprogen Inc, H1 2020
  • Myocardial Infarction - Pipeline by APT Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2020
  • Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H1 2020
  • Myocardial Infarction - Pipeline by Athersys Inc, H1 2020
  • Myocardial Infarction - Pipeline by Axolo Pharma Inc, H1 2020
  • Myocardial Infarction - Pipeline by Bayer AG, H1 2020
  • Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Myocardial Infarction - Pipeline by CardioCreate Inc, H1 2020
  • Myocardial Infarction - Pipeline by Cardiol Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Cardior Pharmaceuticals GmbH, H1 2020
  • Myocardial Infarction - Pipeline by CeleCor Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Celixir Ltd, H1 2020
  • Myocardial Infarction - Pipeline by CellProthera SAS, H1 2020
  • Myocardial Infarction - Pipeline by CFM Pharma Holding BV, H1 2020
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by Domainex Ltd, H1 2020
  • Myocardial Infarction - Pipeline by EndoProtech Inc, H1 2020
  • Myocardial Infarction - Pipeline by Ever Supreme Bio Technology Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Evotec SE, H1 2020
  • Myocardial Infarction - Pipeline by EyeGene Inc, H1 2020
  • Myocardial Infarction - Pipeline by Faraday Pharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by General Regeneratives Shanghai Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Generium, H1 2020
  • Myocardial Infarction - Pipeline by GNT Pharma Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Hemostemix Inc, H1 2020
  • Myocardial Infarction - Pipeline by Honya Medical Inc, H1 2020
  • Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2020
  • Myocardial Infarction - Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
  • Myocardial Infarction - Pipeline by iHeart Japan Corp, H1 2020
  • Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Innolife Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Inotrem SA, H1 2020
  • Myocardial Infarction - Pipeline by IPS Heart Inc, H1 2020
  • Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Kine Sciences, H1 2020
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Myocardial Infarction - Pipeline by LTT Bio-Pharma Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by MandalMed Inc, H1 2020
  • Myocardial Infarction - Pipeline by Marizyme Inc, H1 2020
  • Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2020
  • Myocardial Infarction - Pipeline by MIFCOR Inc, H1 2020
  • Myocardial Infarction - Pipeline by MimeTech Srl, H1 2020
  • Myocardial Infarction - Pipeline by Mirae Cell Bio Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2020
  • Myocardial Infarction - Pipeline by Novartis AG, H1 2020
  • Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2020
  • Myocardial Infarction - Pipeline by OMEICOS Therapeutics GmbH, H1 2020
  • Myocardial Infarction - Pipeline by OP2 Drugs SAS, H1 2020
  • Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2020
  • Myocardial Infarction - Pipeline by OtiTopic LLC, H1 2020
  • Myocardial Infarction - Pipeline by Oxstem Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Pharmahungary Group, H1 2020
  • Myocardial Infarction - Pipeline by Polyphor AG, H1 2020
  • Myocardial Infarction - Pipeline by Primary Peptides Inc, H1 2020
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by Qurgen Inc (Inactive), H1 2020
  • Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by Recardio GmbH, H1 2020
  • Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by ResoTher Pharma ApS, H1 2020
  • Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2020
  • Myocardial Infarction - Pipeline by Sentan Pharma Inc, H1 2020
  • Myocardial Infarction - Pipeline by Serpin Pharma LLC, H1 2020
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2020
  • Myocardial Infarction - Pipeline by SmartPharm Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by Sorrento Therapeutics Inc, H1 2020
  • Myocardial Infarction - Pipeline by T&R Biofab Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Techfields Pharma Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Thrombolytic Science International LLC, H1 2020
  • Myocardial Infarction - Pipeline by Translational Sciences Inc, H1 2020
  • Myocardial Infarction - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
  • Myocardial Infarction - Pipeline by XBiotech Inc, H1 2020
  • Myocardial Infarction - Pipeline by Xcelthera INC, H1 2020
  • Myocardial Infarction - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
  • Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2020
  • Myocardial Infarction - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Myocardial Infarction - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Myocardial Infarction - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Myocardial Infarction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Actinogen Medical Ltd
  • Angion Biomedica Corp
  • Ankasa Regenerative Therapeutics Inc
  • Aposcience AG
  • Applied Therapeutics Inc
  • Aprogen Inc
  • APT Therapeutics Inc
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Axolo Pharma Inc
  • Bayer AG
  • Bharat Biotech Ltd
  • Cadila Healthcare Ltd
  • CardioCreate Inc
  • Cardiol Therapeutics Inc
  • Cardior Pharmaceuticals GmbH
  • CeleCor Therapeutics Inc
  • Celixir Ltd
  • CellProthera SAS
  • CFM Pharma Holding BV
  • Cynata Therapeutics Ltd
  • Diffusion Pharmaceuticals Inc
  • Domainex Ltd
  • EndoProtech Inc
  • Ever Supreme Bio Technology Co Ltd
  • Evotec SE
  • EyeGene Inc
  • Faraday Pharmaceuticals Inc
  • General Regeneratives Shanghai Ltd
  • Generium
  • GNT Pharma Co Ltd
  • Hemostemix Inc
  • Honya Medical Inc
  • HUYA Bioscience International LLC
  • Idorsia Pharmaceutical Ltd
  • iHeart Japan Corp
  • InCarda Therapeutics Inc
  • Innolife Co Ltd
  • Inotrem SA
  • IPS Heart Inc
  • K-Stemcell Co Ltd
  • Kine Sciences
  • Lee's Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll